According to Zhitong Finance App, Jianfan Biotech (300529.SZ) announced that the company plans to use its own funds to transfer 37.60% of the shares of Aiduoduo Health Management (Guangdong Hengqin) Co., Ltd. (“Aiduoduo” for short), with a corresponding transfer price of 17.592 million yuan. Prior to this transaction, Aiduoduo was a 62.40% holding subsidiary of the company. It was mainly engaged in health management and security services in the field of chronic diseases, focusing on providing health consulting services such as personalized health management plans and popular science education for patients with chronic kidney disease. After the transaction, the company held 100% of Aiduoduo's shares, and Aiduoduo became a wholly-owned subsidiary of the company, which is conducive to promoting collaborative business development between the company and Aiduoduo, and further improving the layout of the company's entire blood purification industry chain.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.